Expertise in
7
conditions

Dr. Joseph R. Kelley

Radiation Oncology
Genesiscare Usa Of North Carolina, PA
179 N Buncombe School Rd, 
Weaverville, NC 
Accepting New Patients
Offers Telehealth
Expertise in
7
conditions
Genesiscare Usa Of North Carolina, PA
179 N Buncombe School Rd, 
Weaverville, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Kelley is a Radiation Oncologist in Weaverville, North Carolina. Dr. Kelley is highly rated in 7 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Angiosarcoma of the Scalp, and Metastatic Brain Tumor. Dr. Kelley is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in NC
Hospital Affiliations
Memorial Mission Hospital And Asheville Surgery Ce
The Mcdowell Hospital
Haywood Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Prominence Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

GENESISCARE USA OF NORTH CAROLINA, PA
179 N Buncombe School Rd, Weaverville, NC 28787
Other Locations
GENESISCARE USA OF NORTH CAROLINA, PA
600 Hospital Dr, Suite 10, Clyde, NC 28721
GENESISCARE USA OF NORTH CAROLINA, PA
63 S Medical Ct, Marion, NC 28752
GENESISCARE USA OF NORTH CAROLINA, PA
20 Medical Park Dr, Asheville, NC 28803
GENESISCARE USA OF NORTH CAROLINA, PA
70 Neely Rd, Brevard, NC 28712
GENESISCARE USA OF NORTH CAROLINA, PA
95 Doctors Dr, Hendersonville, NC 28792
GENESISCARE USA OF NORTH CAROLINA, PA
1 Doctors Park, Asheville, NC 28801
GENESISCARE USA OF NORTH CAROLINA, PA
171 Daniel Rd, Forest City, NC 28043

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer
A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

1 Total Publications

Oral microbiome and mycobiome dynamics in cancer therapy-induced oral mucositis.
Oral microbiome and mycobiome dynamics in cancer therapy-induced oral mucositis.
Journal: Scientific data
Published: October 15, 2024
Similar Doctors
Expertise in
21
conditions
Dr. Matthew C. Hull
Radiation Oncology
Expertise in
21
conditions
Dr. Matthew C. Hull
Radiation Oncology

Mission Health Community Multispecialty Providers LLC

509 Biltmore Ave, 
Asheville, NC 
 (9.9 miles away)
828-213-2325
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Hull is a Radiation Oncologist in Asheville, North Carolina. Dr. Hull is highly rated in 21 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET). Dr. Hull is currently accepting new patients.

Expertise in
19
conditions
Dr. Eric F. Kuehn
Radiation Oncology
Expertise in
19
conditions
Dr. Eric F. Kuehn
Radiation Oncology

Mission Health Community Multispecialty Providers LLC

509 Biltmore Ave, 
Asheville, NC 
 (9.9 miles away)
828-213-2325
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eric Kuehn is a Radiation Oncologist in Asheville, North Carolina. Dr. Kuehn is highly rated in 19 conditions, according to our data. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Laryngeal Cancer, and Squamous Cell Skin Carcinoma. Dr. Kuehn is currently accepting new patients.

Expertise in
11
conditions
Dr. Sayyad Y. Zia
Radiation Oncology
Expertise in
11
conditions
Dr. Sayyad Y. Zia
Radiation Oncology

Henderson County Hospital Corporation

805 6th Ave W, 
Hendersonville, NC 
 (28.1 miles away)
828-696-1330
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sayyad Zia is a Radiation Oncologist in Hendersonville, North Carolina. Dr. Zia is highly rated in 11 conditions, according to our data. His top areas of expertise are Tongue Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Familial Prostate Cancer. Dr. Zia is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kelley's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 55 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile